{"nctId":"NCT04760314","briefTitle":"A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis","startDateStruct":{"date":"2021-03-10","type":"ACTUAL"},"conditions":["Dermatitis, Atopic","Dermatitis","Eczema","Skin Diseases","Skin Diseases, Genetic"],"count":286,"armGroups":[{"label":"Lebrikizumab 250 mg Every 4 weeks (Q4W)","type":"EXPERIMENTAL","interventionNames":["Drug: Lebrikizumab","Drug: Topical Corticosteroid"]},{"label":"Lebrikizumab 250 mg Every 2 weeks (Q2W)","type":"EXPERIMENTAL","interventionNames":["Drug: Lebrikizumab","Drug: Topical Corticosteroid"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Topical Corticosteroid"]}],"interventions":[{"name":"Lebrikizumab","otherNames":["LY3650150"]},{"name":"Placebo","otherNames":[]},{"name":"Topical Corticosteroid","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have chronic Atopic Dermatitis (AD) that has been present for ≥1 year before the screening.\n* Have moderate-to-severe AD, including all of the following:\n\n  * EASI score ≥16 at the baseline\n  * IGA score ≥3 (scale of 0 to 4) at the baseline\n  * AD involvement on ≥10% of Body Surface Area (BSA) at the baseline\n* Have a documented history provided by a physician and/or investigator of inadequate response to existing topical medications within 6 months preceding screening as defined by at least 1 of the following:\n\n  * Inability to achieve good disease control, defined as mild disease or better (for example, IGA ≤2) after use of at least a medium-potency topical corticosteroids (TCS) for at least 4 weeks, or for the maximum duration recommended by the product prescribing information (for example, 14 days for super-potent TCS), whichever is shorter. Topical corticosteroids may be used with or without Topical calcineurin inhibitors (TCI) and/or topical Janus Kinase (JAK) inhibitors.\n  * Participants who failed systemic therapies intended to treat AD within 6 months preceding screening, such as cyclosporine, methotrexate (MTX), azathioprine, and mycophenolate mofetil (MMF), will also be considered as surrogates for having inadequate response to topical therapy.\n* Body weight ≥40 kilogram (kg)\n\nExclusion Criteria:\n\n* Have a history of anaphylaxis\n* Have uncontrolled chronic disease that might require bursts of oral corticosteroids for example, comorbid severe uncontrolled asthma within the past 12 months requiring systemic corticosteroid treatment or hospitalization for \\>24 hours at baseline.\n* Have an active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the baseline or superficial skin infections within 1 week before the baseline.\n* Evidence of acute or chronic hepatitis or known liver cirrhosis.\n* Have a history of pneumocystis pneumonia (PCP) or a positive beta-D-glucan test at screening and a confirmed diagnosis of PCP.\n* Have a history of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.\n* Have presence of skin comorbidities (for example, sclerosis, psoriasis, or lupus erythematosus) that may interfere with study assessments.\n* Have presence of significant uncontrolled neuropsychiatric disorder.\n* Have been exposed to a live vaccine within 12 weeks prior to baseline or are expected to need/receive a live vaccine during the study or up to 125 days after the last dose of study drug.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With an Investigators Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16","description":"The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null},{"groupId":"OG001","value":"29.1","spread":null},{"groupId":"OG002","value":"33.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving Eczema Area Severity Index-75 (EASI-75) (≥75% Reduction in EASI Score) at Week 16","description":"The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI-75 score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe).\n\nThe EASI-75 responder is defined as a participant who achieves a ≥ 75% improvement from baseline in the EASI score.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","spread":null},{"groupId":"OG001","value":"47.2","spread":null},{"groupId":"OG002","value":"51.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Eczema Area Severity Index (EASI) Score From Baseline to Week 16","description":"The EASI assesses objective physician estimates of 2 dimensions of AD - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe).\n\nLeast Square (LS) Mean was calculated using ANCOVA model with treatment, stratification factors of geographic region, age group, baseline IGA score (IGA 3 versus 4) as fixed factors baseline value as covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.25","spread":"4.765"},{"groupId":"OG001","value":"-59.74","spread":"4.920"},{"groupId":"OG002","value":"-64.23","spread":"4.402"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving EASI-90 at Week 16","description":"The EASI assesses objective physician estimates of 2 dimensions of AD - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe).\n\nThe EASI-90 responder is defined as a participant who achieves a ≥ 90% reduction from baseline in the EASI score.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":null},{"groupId":"OG001","value":"28.4","spread":null},{"groupId":"OG002","value":"34.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an Itch Numeric Rating Scale (NRS) Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 1","description":"The Itch Numeric Rating Scale (NRS) is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating \"No itch\" and 10 indicating \"Worst itch imaginable.\"","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 2","description":"The Itch Numeric Rating Scale (NRS) is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating \"No itch\" and 10 indicating \"Worst itch imaginable.\"","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.7","spread":null},{"groupId":"OG002","value":"3.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 4","description":"The Itch Numeric Rating Scale (NRS) is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating \"No itch\" and 10 indicating \"Worst itch imaginable.\"","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"8.5","spread":null},{"groupId":"OG002","value":"16.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 16","description":"The Itch Numeric Rating Scale (NRS) is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating \"No itch\" and 10 indicating \"Worst itch imaginable.\"","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":null},{"groupId":"OG001","value":"23.8","spread":null},{"groupId":"OG002","value":"32.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":82},"commonTop":["Pyrexia","Conjunctivitis allergic","Covid-19","Nasopharyngitis","Folliculitis"]}}}